相关实验视频
Updated: May 1, 2026

07:14
Acupuncture in a Rat Model of Asthma
Published on: August 25, 2020
5.8K
深州平配方通过HSP90AA1/MAPK14/PTGS2通路治疗过敏性喘
1Department of Pediatrics, Tongde Hospital of Zhejiang Province, Hangzhou, China.
概括
沈州平配方通过减少免疫细胞招募和气道过敏反应,有效治疗过敏喘 (AA). 这种传统中医药抑制HSP90AA1/MAPK14/PTGS2通路,提供了一种新的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 传统中国医药 传统中国医药
背景情况:
- 沈州平配方是一种中国传统的喘治疗药物.
- 沈州平配方的确切作用机制尚不清楚.
研究的目的:
- 为了评估神州平配方的抗过敏喘 (AA) 特性.
- 用网络药理学和分子对接来预测神州平公式的分子标.
主要方法:
- 过敏性喘模型诱导室内灰尘 (HDMs) 在小鼠.
- 在支气管洗液 (BALF) 中评估气道阻力和免疫细胞数量.
- 网络药理学,分子对接,实时逆转录PCR和西部斑分析.
主要成果:
- 沈州平配方的使用减少了呼吸道的高反应性和免疫细胞的透,包括中性粒细胞.
- 预测了IL-17信号通路内的关键目标,包括HSP90AA1,PTGS2和MAPK14.
- 分子对接证实了沃贡因与这些点的强烈结合亲和关系.
- 这种配方降低了HSP90AA1,PTGS2和MAPK14在患有HDM的小鼠肺部的表达.
结论:
- 沈州平配方显示出显著的抗过敏喘效应.
- 该配方的有效性归因于抑制HSP90AA1/MAPK14/PTGS2通路,涉及减少中性粒细胞的招募.
相关概念视频
The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Asthma I: Introduction
112
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
112

